Insider Trading February 6, 2026

Qualys CFO Disposes $873K in Stock; Company Posts Q4 Beat as Analyst Lowers Target

Kim Joo Mi sold 7,199 shares under a 10b5-1 plan; Qualys reported stronger-than-expected Q4 2025 results while Truist trims its price target citing growth headwinds

By Jordan Park QLYS
Qualys CFO Disposes $873K in Stock; Company Posts Q4 Beat as Analyst Lowers Target
QLYS

Qualys Chief Financial Officer Kim Joo Mi sold 7,199 shares of common stock on February 4, 2026, under a pre-arranged 10b5-1 trading plan, generating $873,369. The company also reported fourth-quarter 2025 results that exceeded consensus on both earnings per share and revenue, even as Truist Securities cut its price target and flagged a slight dip in net dollar retention tied to new product ramps.

Key Points

  • Qualys CFO Kim Joo Mi sold 7,199 shares on February 4, 2026, under a pre-arranged 10b5-1 plan for $873,369.
  • Qualys beat fourth-quarter 2025 estimates with EPS of $1.87 and revenue of $175.28 million.
  • Truist Securities trimmed its price target to $120 from $130 and maintained a Hold rating, pointing to a slight decline in net dollar retention related to new product ramps.

Qualys, Inc. (NASDAQ: QLYS) disclosed a planned sale of company shares by its chief financial officer, Kim Joo Mi, in a Form 4 filing with the Securities and Exchange Commission. On February 4, 2026, Kim sold a total of 7,199 shares of Qualys common stock under a 10b5-1 trading arrangement, with the transactions producing a combined value of $873,369.

The filing details that the disposition occurred across multiple transactions at incremental prices ranging from $125.253 to $129.755 per share. The tranche breakdown reported was as follows:

  • 500 shares sold at a weighted average price of $125.253
  • 400 shares sold at $126.74
  • 2,051 shares sold at $128.1983
  • 3,648 shares sold at $129.156
  • 200 shares sold at $129.755

After completing these sales, Kim Joo Mi is recorded as directly owning 88,489 shares of Qualys.

Separately, Qualys released its fourth-quarter 2025 financial results, reporting an earnings per share of $1.87, above the Wall Street forecast of $1.78. Revenue for the quarter came in at $175.28 million, surpassing the expected $173.15 million. Those metrics indicate the company outperformed consensus estimates on both profitability and top-line figures for the period.

Despite the better-than-expected quarter, Truist Securities adjusted its valuation view on Qualys, lowering its price target from $130 to $120 while maintaining a Hold rating. Truist cited growth concerns as the rationale for the reduction, pointing to a modest decline in the net dollar retention rate to 103% from 104% in the prior quarter. The broker linked that decrease to the ramp-up of newer products.

The combination of an insider sale, solid quarterly results, and a more cautious analyst outlook illustrates a mixed signal for investors: strong near-term financial performance paired with measured concern about the companys growth trajectory as it integrates newer offerings.


Key financials and corporate actions summarized:

  • Insider sale: 7,199 shares by CFO Kim Joo Mi on February 4, 2026, under a 10b5-1 plan, totaling $873,369.
  • Ownership post-sale: Kim directly holds 88,489 shares.
  • Q4 2025 results: EPS $1.87 vs. $1.78 estimate; revenue $175.28 million vs. $173.15 million estimate.
  • Analyst action: Truist cuts price target to $120 from $130, retains Hold, cites net dollar retention decline from 104% to 103% tied to new product ramps.

Risks

  • Analyst concern over growth - Truist cited a decline in net dollar retention to 103% from 104%, indicating potential near-term revenue momentum risks tied to product integration (affects software/SaaS sector and investor sentiment).
  • Insider selling - the CFOs sale, while executed under a 10b5-1 plan, represents a material disposition that some investors may view as a signal of liquidity needs or portfolio rebalancing (impacts shareholder perception and stock trading dynamics).

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026